THOUSAND OAKS, Calif., November 13, 2006 -- Amgen (NASDAQ: AMGN), today announced that data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing ...
Please provide your email address to receive an email when new articles are posted on . In a 4-year study, more than half of patients with psoriatic arthritis enrolled in a trial of Enbrel remained ...
THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results